Briefing
Advancing metabolic research with Truveta
Metabolic research is evolving rapidly as new therapies reshape the treatment landscape across obesity, diabetes, MASH, endocrine disorders, and rare inherited metabolic diseases.
Generating credible evidence requires complete, representative, and real-time clinical data that capture disease progression, treatment response, safety, and long-term outcomes. This briefing explores how Truveta enables high-quality metabolic real-world evidence generation using daily refreshed EHR data enriched with laboratory results, clinical notes, body composition measures, social determinants of health, claims, and mortality.
Download the briefing to explore how:
- Multimodal clinical data—including HbA1c, fasting glucose, liver and lipid biomarkers, BMI and weight history, and AI-extracted clinical concepts—support precise characterization of metabolic disease.
- Longitudinal laboratory, weight, body composition, and treatment data enable clinically meaningful metabolic endpoints and outcomes research.
- Large, representative populations support research across obesity, diabetes, MASH, endocrine disorders, and rare inherited metabolic diseases.
- Daily refreshed data support earlier identification of treatment patterns, safety signals, and shifts in metabolic care.
- Linked EHR, claims, mortality, SDOH, and mother-child data support evidence generation across the product lifecycle.
